Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | GSK3A | P49840 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6074980 | 0.90 | SMN1; SMN2 (0.58) | ALDH1A1MAPTSMN1; SMN2HPGDKDM4E | |
| Hydrochloric Acid SCHEMBL3845432 | 0.88 | ALDH1A1 (0.43) | ALDH1A1MAPTSMN1; SMN2MAPK1TDP1 | |
| Bromide SCHEMBL3845509 | 0.88 | NPC1 (0.46) | ALDH1A1MAPTSMN1; SMN2MAPK1TDP1 | |
| Bromide SCHEMBL2530948 | 0.87 | LMNA (0.49) | ALDH1A1MAPTSMN1; SMN2MAPK1CYP3A4 | |
| Hydrochloric Acid SCHEMBL3846002 | 0.87 | ALDH1A1 (0.56) | ALDH1A1MAPTSMN1; SMN2MAPK1TDP1 | |
| Bromide SCHEMBL6074208 | 0.86 | KMT2A (0.46) | ALDH1A1MAPTSMN1; SMN2TDP1HPGD | |
| SCHEMBL28841390 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPTSMN1; SMN2MAPK1TDP1 | |
| Hydrochloric Acid SCHEMBL10529156 | 0.85 | KMT2A (0.41) | ALDH1A1MAPTSMN1; SMN2MAPK1TDP1 | |
| SCHEMBL10529513 | 0.85 | HRH1 (0.51) | ALDH1A1MAPTSMN1; SMN2MAPK1TDP1 | |
| Bromide SCHEMBL6010080 | 0.85 | ALDH1A1 (0.52) | ALDH1A1MAPTSMN1; SMN2HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022721-B1 | Method and composition for rejuvenating cells, tissues, organs, hair and nails | ULRICH PETER C | 2006-04-04 | — | — | US | disclosed |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | ULRICH PETER C | 2005-11-03 | — | — | US | disclosed |
| US-6777557-B2 | Method and composition for rejuvenating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2004-08-17 | — | — | US | disclosed |
| EP-1098647-A4 | COMPOUNDS AND COMPOSITIONS FOR TREATING TISSUE ISCHEMIA | LONG ISLAND JEWISH RES INST (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-12 | — | — | US | disclosed |
| US-6391899-B1 | STROKE THERAPY; CARDIOVASCULAR DISORDERS | North Shore—Long Island Jewish Research Institute | 2002-05-21 | — | — | US | disclosed |
| EP-1098647-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING TISSUE ISCHEMIA | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000003711-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING TISSUE ISCHEMIA | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | ALDH1A1 3396/4885MAPT 1442/4885SMN1; SMN2 2608/4885 |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | ALDH1A1 3396/4885MAPT 1442/4885SMN1; SMN2 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.